IBDEI1XG ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30786,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
;;^UTILITY(U,$J,358.3,30786,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,30786,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,30787,0)
;;=I13.10^^123^1587^9
;;^UTILITY(U,$J,358.3,30787,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30787,1,3,0)
;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
;;^UTILITY(U,$J,358.3,30787,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,30787,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,30788,0)
;;=I15.1^^123^1587^11
;;^UTILITY(U,$J,358.3,30788,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30788,1,3,0)
;;=3^Hypertension Secondary to Oth Renal Disorders
;;^UTILITY(U,$J,358.3,30788,1,4,0)
;;=4^I15.1
;;^UTILITY(U,$J,358.3,30788,2)
;;=^5007072
;;^UTILITY(U,$J,358.3,30789,0)
;;=I15.2^^123^1587^10
;;^UTILITY(U,$J,358.3,30789,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30789,1,3,0)
;;=3^Hypertension Secondary to Endocrine Disorders
;;^UTILITY(U,$J,358.3,30789,1,4,0)
;;=4^I15.2
;;^UTILITY(U,$J,358.3,30789,2)
;;=^5007073
;;^UTILITY(U,$J,358.3,30790,0)
;;=I50.1^^123^1587^16
;;^UTILITY(U,$J,358.3,30790,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30790,1,3,0)
;;=3^Left Ventricular Failure
;;^UTILITY(U,$J,358.3,30790,1,4,0)
;;=4^I50.1
;;^UTILITY(U,$J,358.3,30790,2)
;;=^5007238
;;^UTILITY(U,$J,358.3,30791,0)
;;=E26.09^^123^1587^17
;;^UTILITY(U,$J,358.3,30791,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30791,1,3,0)
;;=3^Primary Hyperaldosteronism,Other
;;^UTILITY(U,$J,358.3,30791,1,4,0)
;;=4^E26.09
;;^UTILITY(U,$J,358.3,30791,2)
;;=^5002735
;;^UTILITY(U,$J,358.3,30792,0)
;;=I15.8^^123^1587^18
;;^UTILITY(U,$J,358.3,30792,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30792,1,3,0)
;;=3^Secondary Hypertension,Other
;;^UTILITY(U,$J,358.3,30792,1,4,0)
;;=4^I15.8
;;^UTILITY(U,$J,358.3,30792,2)
;;=^5007074
;;^UTILITY(U,$J,358.3,30793,0)
;;=E27.5^^123^1587^1
;;^UTILITY(U,$J,358.3,30793,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30793,1,3,0)
;;=3^Adrenomedullary Hyperfunction
;;^UTILITY(U,$J,358.3,30793,1,4,0)
;;=4^E27.5
;;^UTILITY(U,$J,358.3,30793,2)
;;=^5002744
;;^UTILITY(U,$J,358.3,30794,0)
;;=E26.01^^123^1587^4
;;^UTILITY(U,$J,358.3,30794,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30794,1,3,0)
;;=3^Conn's Syndrome
;;^UTILITY(U,$J,358.3,30794,1,4,0)
;;=4^E26.01
;;^UTILITY(U,$J,358.3,30794,2)
;;=^329905
;;^UTILITY(U,$J,358.3,30795,0)
;;=I15.9^^123^1587^19
;;^UTILITY(U,$J,358.3,30795,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30795,1,3,0)
;;=3^Secondary Hypertension,Unspec
;;^UTILITY(U,$J,358.3,30795,1,4,0)
;;=4^I15.9
;;^UTILITY(U,$J,358.3,30795,2)
;;=^5007075
;;^UTILITY(U,$J,358.3,30796,0)
;;=B20.^^123^1588^3
;;^UTILITY(U,$J,358.3,30796,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30796,1,3,0)
;;=3^HIV Disease
;;^UTILITY(U,$J,358.3,30796,1,4,0)
;;=4^B20.
;;^UTILITY(U,$J,358.3,30796,2)
;;=^5000555
;;^UTILITY(U,$J,358.3,30797,0)
;;=J18.9^^123^1588^6
;;^UTILITY(U,$J,358.3,30797,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30797,1,3,0)
;;=3^Pneumonia,Unspec Organism
;;^UTILITY(U,$J,358.3,30797,1,4,0)
;;=4^J18.9
;;^UTILITY(U,$J,358.3,30797,2)
;;=^95632
;;^UTILITY(U,$J,358.3,30798,0)
;;=J10.1^^123^1588^1
;;^UTILITY(U,$J,358.3,30798,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30798,1,3,0)
;;=3^Flu w/ Respiratory Manifestations
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XG 3753 printed Apr 09, 2024@20:52:50 Page 2
IBDEI1XG ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30786,1,3,0)
+2 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
+3 ;;^UTILITY(U,$J,358.3,30786,1,4,0)
+4 ;;=4^I13.0
+5 ;;^UTILITY(U,$J,358.3,30786,2)
+6 ;;=^5007067
+7 ;;^UTILITY(U,$J,358.3,30787,0)
+8 ;;=I13.10^^123^1587^9
+9 ;;^UTILITY(U,$J,358.3,30787,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,30787,1,3,0)
+12 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
+13 ;;^UTILITY(U,$J,358.3,30787,1,4,0)
+14 ;;=4^I13.10
+15 ;;^UTILITY(U,$J,358.3,30787,2)
+16 ;;=^5007068
+17 ;;^UTILITY(U,$J,358.3,30788,0)
+18 ;;=I15.1^^123^1587^11
+19 ;;^UTILITY(U,$J,358.3,30788,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,30788,1,3,0)
+22 ;;=3^Hypertension Secondary to Oth Renal Disorders
+23 ;;^UTILITY(U,$J,358.3,30788,1,4,0)
+24 ;;=4^I15.1
+25 ;;^UTILITY(U,$J,358.3,30788,2)
+26 ;;=^5007072
+27 ;;^UTILITY(U,$J,358.3,30789,0)
+28 ;;=I15.2^^123^1587^10
+29 ;;^UTILITY(U,$J,358.3,30789,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,30789,1,3,0)
+32 ;;=3^Hypertension Secondary to Endocrine Disorders
+33 ;;^UTILITY(U,$J,358.3,30789,1,4,0)
+34 ;;=4^I15.2
+35 ;;^UTILITY(U,$J,358.3,30789,2)
+36 ;;=^5007073
+37 ;;^UTILITY(U,$J,358.3,30790,0)
+38 ;;=I50.1^^123^1587^16
+39 ;;^UTILITY(U,$J,358.3,30790,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,30790,1,3,0)
+42 ;;=3^Left Ventricular Failure
+43 ;;^UTILITY(U,$J,358.3,30790,1,4,0)
+44 ;;=4^I50.1
+45 ;;^UTILITY(U,$J,358.3,30790,2)
+46 ;;=^5007238
+47 ;;^UTILITY(U,$J,358.3,30791,0)
+48 ;;=E26.09^^123^1587^17
+49 ;;^UTILITY(U,$J,358.3,30791,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,30791,1,3,0)
+52 ;;=3^Primary Hyperaldosteronism,Other
+53 ;;^UTILITY(U,$J,358.3,30791,1,4,0)
+54 ;;=4^E26.09
+55 ;;^UTILITY(U,$J,358.3,30791,2)
+56 ;;=^5002735
+57 ;;^UTILITY(U,$J,358.3,30792,0)
+58 ;;=I15.8^^123^1587^18
+59 ;;^UTILITY(U,$J,358.3,30792,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,30792,1,3,0)
+62 ;;=3^Secondary Hypertension,Other
+63 ;;^UTILITY(U,$J,358.3,30792,1,4,0)
+64 ;;=4^I15.8
+65 ;;^UTILITY(U,$J,358.3,30792,2)
+66 ;;=^5007074
+67 ;;^UTILITY(U,$J,358.3,30793,0)
+68 ;;=E27.5^^123^1587^1
+69 ;;^UTILITY(U,$J,358.3,30793,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,30793,1,3,0)
+72 ;;=3^Adrenomedullary Hyperfunction
+73 ;;^UTILITY(U,$J,358.3,30793,1,4,0)
+74 ;;=4^E27.5
+75 ;;^UTILITY(U,$J,358.3,30793,2)
+76 ;;=^5002744
+77 ;;^UTILITY(U,$J,358.3,30794,0)
+78 ;;=E26.01^^123^1587^4
+79 ;;^UTILITY(U,$J,358.3,30794,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,30794,1,3,0)
+82 ;;=3^Conn's Syndrome
+83 ;;^UTILITY(U,$J,358.3,30794,1,4,0)
+84 ;;=4^E26.01
+85 ;;^UTILITY(U,$J,358.3,30794,2)
+86 ;;=^329905
+87 ;;^UTILITY(U,$J,358.3,30795,0)
+88 ;;=I15.9^^123^1587^19
+89 ;;^UTILITY(U,$J,358.3,30795,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,30795,1,3,0)
+92 ;;=3^Secondary Hypertension,Unspec
+93 ;;^UTILITY(U,$J,358.3,30795,1,4,0)
+94 ;;=4^I15.9
+95 ;;^UTILITY(U,$J,358.3,30795,2)
+96 ;;=^5007075
+97 ;;^UTILITY(U,$J,358.3,30796,0)
+98 ;;=B20.^^123^1588^3
+99 ;;^UTILITY(U,$J,358.3,30796,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,30796,1,3,0)
+102 ;;=3^HIV Disease
+103 ;;^UTILITY(U,$J,358.3,30796,1,4,0)
+104 ;;=4^B20.
+105 ;;^UTILITY(U,$J,358.3,30796,2)
+106 ;;=^5000555
+107 ;;^UTILITY(U,$J,358.3,30797,0)
+108 ;;=J18.9^^123^1588^6
+109 ;;^UTILITY(U,$J,358.3,30797,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,30797,1,3,0)
+112 ;;=3^Pneumonia,Unspec Organism
+113 ;;^UTILITY(U,$J,358.3,30797,1,4,0)
+114 ;;=4^J18.9
+115 ;;^UTILITY(U,$J,358.3,30797,2)
+116 ;;=^95632
+117 ;;^UTILITY(U,$J,358.3,30798,0)
+118 ;;=J10.1^^123^1588^1
+119 ;;^UTILITY(U,$J,358.3,30798,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,30798,1,3,0)
+122 ;;=3^Flu w/ Respiratory Manifestations
